1. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 11 (November 2017) Authors: Catenacci, Daniel V T; Tebbutt, Niall C; Davidenko, Irina; Murad, André M; Al-Batran, Salah-Eddin; Ilson, David H; Tjulandin, Sergei; Gotovkin, Evengy; Karaszewska, Boguslawa; Bondarenko, Igor; Tejani, Mohamedtaki A; Udrea, Anghel A; Tehfe, Mustapha; De Vita, Ferdinando; Turkington, Cheryl; Tang,... Journal: Lancet oncology Issue: Volume 18:Issue 11(2017:Nov.) Page Start: 1467 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗